Recro Expands Manufacturing Capabilities
Recro, a wholly-owned subsidiary of Recro Pharma, Inc, has expanded its capabilities by adding a new tablet manufacturing suite and growing its development team. An FDA- and DEA-approved leading provider of solid oral dose manufacturing services for the pharmaceutical industry, Recro specializes in extended release and controlled substances.
“As long-term leaders in the development of extended release technology, we pride ourselves in meeting our clients’ exact standards,” said Scott Rizzo, general manager. “By expanding our equipment line and adding nearly a dozen more scientists to our team, we are able to offer yet more services to meet our clients’ needs.”
Specializing in formulation, reformulation, analytical method development, manufacturing and packaging and logistics services, Recro is one of only a few contract manufacturing and development organizations capable of taking delayed release, sustained release or combination release products from development to commercialization.
The company’s new suite includes a state-of-the-art tablet press, the Fette FE 55, and a new film coater, the Bohle BTC-100.
“Our new tablet press will enable us to compress single- and bi-layer tablets at commercial speeds,” Rizzo said. “The new equipment further demonstrates our commitment to remain a leader in the solid dose manufacturing world.”
Recro provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. Specializing in extended release solid dose and DEA controlled substances, Recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. For more information about Recro’s flexible, CDMO solutions, visit https://www.recrogainesville.com/.